113 related articles for article (PubMed ID: 22252757)
1. The prognostic significance of the immunohistochemical expression of P53 and BCL-2 in endometrial cancer.
Dobrzycka B; Terlikowski SJ; Garbowicz M; Niklinski J; Chyczewski L; Kulikowski M
Folia Histochem Cytobiol; 2011; 49(4):631-5. PubMed ID: 22252757
[TBL] [Abstract][Full Text] [Related]
2. P53 and BCL-2 as prognostic markers in endometrial carcinoma.
Appel ML; Edelweiss MI; Fleck J; Rivero LF; Rivoire WA; Mônego HI; Dos Reis R
Pathol Oncol Res; 2008 Mar; 14(1):23-30. PubMed ID: 18398703
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma.
Coppola D; Fu L; Nicosia SV; Kounelis S; Jones M
Hum Pathol; 1998 May; 29(5):455-62. PubMed ID: 9596268
[TBL] [Abstract][Full Text] [Related]
4. [Expression of p53 protein in women with endometrial cancer].
Ivanov S; Khadzhiolov N; Ivanov S
Akush Ginekol (Sofiia); 2001; 40(4):14-5. PubMed ID: 11803862
[TBL] [Abstract][Full Text] [Related]
5. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings.
Saegusa M; Okayasu I
J Cancer Res Clin Oncol; 1997; 123(8):429-34. PubMed ID: 9292705
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
[TBL] [Abstract][Full Text] [Related]
9. Selected immunohistochemical prognostic factors in endometrial cancer.
Markova I; Duskova M; Lubusky M; Kudela M; Zapletalová J; Procházka M; Pilka R
Int J Gynecol Cancer; 2010 May; 20(4):576-82. PubMed ID: 20686376
[TBL] [Abstract][Full Text] [Related]
10. bcl-2 and p53 in endometrial adenocarcinoma.
Taskin M; Lallas TA; Barber HR; Shevchuk MM
Mod Pathol; 1997 Jul; 10(7):728-34. PubMed ID: 9237185
[TBL] [Abstract][Full Text] [Related]
11. BCL-2 and P53 expression in endometrial carcinoma.
Erkanli S; Eren F; Pekin S; Bagis T
J Exp Clin Cancer Res; 2004 Mar; 23(1):97-103. PubMed ID: 15149157
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes.
Kalogiannidis I; Bobos M; Papanikolaou A; Makedos A; Amplianitis I; Vergote I; Nenopoulou E; Makedos G
Eur J Gynaecol Oncol; 2008; 29(1):19-25. PubMed ID: 18386458
[TBL] [Abstract][Full Text] [Related]
13. The relationship between expression of p53/bcl-2 and clinicopathological criteria in endometrioid adenocarcinomas of the endometrium.
Sari I; Gocmen A; Bitiren M; Cakmak EA
Eur J Gynaecol Oncol; 2004; 25(1):79-80. PubMed ID: 15053067
[TBL] [Abstract][Full Text] [Related]
14. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression.
Sivridis E; Giatromanolaki A; Koukourakis M; Anastasiadis P
Virchows Arch; 2001 May; 438(5):470-7. PubMed ID: 11407475
[TBL] [Abstract][Full Text] [Related]
15. Immunoexpression of PAX 8 in endometrial cancer: relation to high-grade carcinoma and p53.
Brunner AH; Riss P; Heinze G; Meltzow E; Brustmann H
Int J Gynecol Pathol; 2011 Nov; 30(6):569-75. PubMed ID: 21979593
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
[TBL] [Abstract][Full Text] [Related]
17. Bax, Bcl-2, and p53 expression in endometrial cancer.
Sakuragi N; Salah-eldin AE; Watari H; Itoh T; Inoue S; Moriuchi T; Fujimoto S
Gynecol Oncol; 2002 Sep; 86(3):288-96. PubMed ID: 12217750
[TBL] [Abstract][Full Text] [Related]
18. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.
Alkushi A; Lim P; Coldman A; Huntsman D; Miller D; Gilks CB
Int J Gynecol Pathol; 2004 Apr; 23(2):129-37. PubMed ID: 15084841
[TBL] [Abstract][Full Text] [Related]
19. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors.
Menezes HL; Jucá MJ; Gomes EG; Nunes BL; Costa HO; Matos D
Arq Gastroenterol; 2010; 47(2):141-7. PubMed ID: 20721457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
